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1. I n t roduct ion  
Among the numerous antibiotics known to act on 
the larger ibosomal subunit [2, 3] a group consisting 
of gougerotin (1), blasticidin S (2), amicetin (3) and 
bamicetin (4), can clearly be delineated on the basis 
of their mode of action and their structural subunits, 
suggesting [4] the term aminoacyl-4-aminohexosyl- 
cytosine group of antibiotic inhibitors. The effects of 
the first three (1-3)  on protein synthesis have been 
studied in great detail using various model systems 
with washed bacterial ribosomes [2, 3], native poly- 
ribosomes from E. coli [5] as well as with yeast [6, 7] 
and mammalian [7-9] ribosomal systems, whilst the 
inhibitory behaviour of bamicetin (4) in several bac- 
terial model reactions has been evaluated only recently 
[4]. With respect to the transpeptidation step the inhibi- 
tory patterns of this group of antibiotics (1-4)  are 
similar enough as to suggest competition for similar or 
even identical sites within the ribosomal peptidyl 
transferase, conceivably those associated with the 
aminoacyl as well as the cytosine recognition regions 
for the CCA-amino acid terminus of native tRNAs. 
Hence, it is dearly worthwhile looking for conformi- 
ties between the molecular architecture of these 
aminoacyl aminohexosyl cytosine antibiotics and 
their mode of action. 
* See [1]. 
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First assessments of the structural features of pyri- 
midine and purine nucleoside antibiotics were under- 
taken by Fox et al. [10], who proposed - as require- 
ments for affecting protein synthesis - an 'accessible' 
amino acid moiety attached to a 'carrier' nucleoside 
together with two basic centers at opposite sites of 
the molecule, one being the amino group of the 
amino acid, the other a nitrogen of the nucleobase 
(i.e. cytosine amino group) or, in the case of amicetin, 
the dimethylamino moiety in the disaccharide por- 
tion. These characterizations, however, are not with- 
out contradiction~ since the somewhat exotic amino- 
acyl components of antibiotics 1-4,  to which the 
growing peptide chain cannot be transferred, are in- 
commensurable with antibiotics of the puromycin 
type. Furthermore, the pK a values of the respective 
groups in compounds 1=-4 differ within too wide a 
range as to effect - in the same functional way - the 
activity of ribosomal peptidyl transferase which in 
fact shows a pH dependance suggesting the involve- 
ment of a functional group with a pK a value in the 
range of 7.5-8 [11]. 
In connection with related studies aimed at tracing 
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down structure-activity relationships of aminoacyl 
aminosugar nucleosides, we embarked on correlating 
inhibitory activity of the antibiotics 1-4, as well as 
their presently available analogs with their structural 
and stereochemical characteristics. The results we 
render significant enough as to be presented. 
2. Major structural features of antibiotics 1 -4  
A [3 C 
Fig. 2. Commensurability of the N,O,N,N-arrangements wi h- 
in the nucleoside portions of gougerotin/blasticidin S(A) with 
those of amieetin and bamicetin (B); a superposition fA on 
B is represented byC. 
With respect o the molecular architecture of the 
aminoacyl aminohexosyl cytosine antibiotics gougero- 
tin, blasticidin S, amicetin and bamicetin (1-4),  four 
major characteristic structural features, common to 
each, may be elicited from space-filling models or - 
more instructively - from Dreiding stereomodels 
(fig. 1): 
I. The spatial arrangement of one oxygen and three 
nitrogen atoms is the same in the respective nucle- 
obase portions. In gougerotin and blasticidin S, these 
are represented by N-l, N-3, N-4 and C-2-carbonyl 
oxygen atoms of the cytosine moiety (fig. 2A). In the 
case of amicetin and bamicetin, respectively, the same 
nitrogen atoms are involved, yet the order is reversed, 
whilst the oxygen atom is supplied by the amide oxy. 
gen of the p-aminobenzoyl moiety (fig. 2B). This con- 
gruity may best be demonstrated by superposing A on 
B as displayed in C. 
II. A second characteristic grouping is being found in 
the same distance from the first structural feature and 
within an identical spatial arrangement; anamide 
bond representing the connecting link between the 
respective aminoacyl residues and the 4-aminohexu- 
ronic acid or 4-aminobenzoic a id moieties. The car- 
bonyl portion of this 'peptide link' is derived from 
D-serine (gougerotin), e-N-methyl-13-arginine (blastici- 
din S) and a-methyl-L-serine (amicetin and bamicetin); 
the amino part of this amide bond is represented by 
the 4-amino group found in each hexuronic acid (for 
1 and 2) and in p-aminobenzoic a id (for 3 and 4). 
III. The carbonyl portion of this 'peptide link' is part 
of a further structural and steric conformity within 
antibiotics 1-4. All four compounds are capable of 
developing an identical steric arrangement of a 
hydroxyl or an amino group in relation to the rest of 
the molecule, as illustrated in the stereomodels (fig. 2) 
by an admittedly arbitrary hydrogen bonding of - 
OH .... OC-type in the serine portions of 1, 3 and 4 and 
of the type-NH 2"--'O=C in the arginine moiety of 2. 
IV. Besides these sterically fixed structural character- 
istics a spatially less localized functional feature can 
be deduced from the structures of the four antibiotics: 
a 'terminal' N-methylamino group. In gougerotin and 
blasticidin S this grouping is contained in the sarcosyl- 
and N-methyl guanidine parts, respectively, whilst 
arnicetin and bamicetin exhibit methylamino functions 
in their disaccharide portions. 
Some conformational nd functional group aspects 
contributing to the total activity may have been omit- 
ted, e.g., the carboxamide or carboxylic acid function 
in gougerotin and blasticidin S, that is unparalleled in
amicetin and bamicetin, as well as others. Neverthe- 
less, the four characteristic features outlined above 
appear to be the minimal structural requirements for 
inhibition of protein biosynthesis within this group of 
antibiotics-a conclusion, that is sustained by the in- 
hibitory behaviour of the presently available analogs. 
3. Evaluation of analogs 
The evaluation of the analogs 5-28 with respect o 
their effects on protein synthesis, hows that none of 
these structural features may be altered or removed 
without substantial or complete loss of inhibitory ac- 
tivity. 
Replacement of the cytosine moiety in blasticidin 
S (2) by uracil ('desaminoblasticidin' 16)-a modifica- 
tion within the first structural element-results in a 
diminution of inhibitory activity to one thousandth 
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or less [12]. As compared to this, alterations in the 
connecting link between the structural elements I 
and II appear to be less incisive. Replacement of the 
5'-carboxamido/'unction by a carbomethoxy or a N, 
N-dimethyl carbamido group (compounds 7 and 6, 
resp.) results in reduced inhibitory activity (about 1.0% 
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of that of gougerotin [13]). Similarly, the correspond- 
ing N- methyl carbamido (5 [13]) and hydroxymethyl 
analogs (8114,15]) exhibited adecrease in biological 
activity and are only about one third as active [13, 
161. 
A very pronounced effect on the inhibitory behav- 
iour seems to be exerted by changes in distance be- 
tween structural features I and II or their direction. 
As exemplified by fig. 3, gougerotin and its active 5'- 
hydroxymethyl analog 8 have identical molecular 
geometry with respect to features I and II, whereas in 
the entirely inactive analogue 9 [ 16,17], deviating 
from 8 only in the linkage of the peptide unit to the 
pyranoid amino function, the geometrical rrange- 
ments between cytosine nucleobase and the peptide 
link are distinctly different. Hence, it is not surprising 
that the gougerotin analog 10 [ 17] lacking structural 
as well as steric essentials, is devoid of any activity 
with respect to interference with protein synthesis at 
the peptide longation stage [16]. For the same rea- 
8 
Fig. 3. Dreiding stereomodels of gougerotin analogs 8 and 9 
as compared togougerotin (1), clearly sho~ ing the congruity 
of 1 and 8 in gross tereochemical features incontrast to the 
disdistinctly different molecular geometry of 9. 
sons, analogs of 10 with glycine, ~arcosine, L-alanine, 
D-phenylalanine, L-lysine, and L-glutamine 7-methyl 
ester as aminoacyl components-which have been pre- 
pared [18] but apparently not evaluated biologically- 
are likely to be inactive. 
Analogs of these antibiotics that lack the amino- 
acyl part altogether - and hence are missing structur- 
al elements II and III - show very little, if any, capa- 
bilities for interfering with the transpeptidation step. 
Thus, cytosinine (18), the nucleoside portion of blast- 
icin S, is devoid of any activity [12], whilst plicacetin 
(23), missing the methylserine part of amicetin and 
thus being either its biological precursor or degrada- 
tion product, is nearly inactive in this respect [4] -  
despite its reported antibacterial ctivity [ 19]. Corre- 
spondingly, a number of plicacetin analogues (24- 
27) that exhibit an antibacterial 'spectrum similar to 
amicetin [19], are likely to be inactive with respect to 
interference with peptide chain elongation. In this 
context, it would be interesting to learn about he bio- 
activity of cytimidine (28) [20], which exhibits truc- 
tural features II-II I, and, consequently, would be a 
closer functional analogue to amicetin than plicacetin. 
Changes in the structural elements III are likewise 
accompanied with either some or complete loss of 
biological activity. Cytomycin (17), for example, is an 
extremely close analogue of blasticidin S, and is near- 
ly inactive [12]. Thus, expectedly, compounds 19-22, 
which have much less resemblance to blasticidin S in 
their aminoacyl parts than cytomycin, exhibit either 
no or only minimal inhibitory activity [21 ]. Varia- 
tions of the sarcosyl-D-seryl unit in gougerotin simi- 
larly seems to lead to a decrease of biological activity 
as evidenced by the compounds 11-15 [ 15 ], all being 
less active [13] than the hydroxymethyl analog 8. 
Additional syntheses and testing of analogous com- 
pounds will certainly be required to render these 
structural rationalizations less tentative and to fully 
define the interactions of these inhibitors with their 
biological receptor, which in turn may help to eluci- 
date the molecular architecture of the active centre of 
the peptidyl transferase. For the moment, these struc- 
ture-activity rationalizations should serve to more ef- 
fectively concentrate synthetic strategies in this field 
towards compounds of biological significance. 
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